Skip to content

WellCareChina

Independent medical information for international patients

Menu

Disease

Stomach cancer胃癌

ICD-10: C16 — Malignant neoplasm of stomach

Group: Cancer Specialty: Gastrointestinal Surgery

Key figures

Published values only. Every tile opens the section that carries its source, its year and its caliber.

Disease details

Standard Chinese name
胃癌
English name
Malignant neoplasm of stomach

Values written in Chinese are quoted as published by the source.

Also known as

  • Gastric cancer
  • Gastric adenocarcinoma

Treatment cost ranges

Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.

Treatment path Cost range Price basis Data year
Surgery 手术 54000 – 80040 CNY Condition package price 病种打包全包价 2020–2025
Radiotherapy 放疗 42000 – 50000 CNY Per-item price 项目价 2025–2026
Chemotherapy 化疗 6550 – 9500 CNY Condition package price 病种打包全包价 2020–2021
Targeted therapy 靶向 84000 – 105000 CNY Per-item price 项目价 2024–2025
Immunotherapy 免疫 36720 – 145080 CNY Per-item price 项目价 2024–2025

The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 145080 CNY. Each row keeps its own data year and caliber.

5 cost ranges for this condition, each with its source on the row page.

Values written in Chinese are quoted as published by the source.

See all cost ranges →

Five-year survival

5-year survival rate 35.2% 95% CI 35.0–35.4

Population
Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
Period
2019–2021
Publisher
National Cancer Center 国家癌症中心
Value nature
Estimated value (hybrid analysis) 估计值（混合法）
Registry scope
281 population-based cancer registries 281 个肿瘤登记处
Stage data availability
Not published

Values written in Chinese are quoted as published by the source.

See all survival rates →

How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.

Hospitals with a published record for this condition

Selected using official public data sources

These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.

How these hospitals were selected

Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.

Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.

Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.

When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.

The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.

  1. West China Hospital, Sichuan University四川大学华西医院

    Chengdu 成都市

    National key clinical specialty

    Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.

  2. Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院

    Beijing 北京市

    National key clinical specialty

    Published research

    PubMed indexes 1 paper on this condition that names this hospital.

    Also ranked: Thoracic Surgery #1, Medical Oncology #1, Urology nominated in the Fudan list.

  3. China-Japan Friendship Hospital中日友好医院

    Beijing 北京市

    National key clinical specialty

    Published research

    1 more published study

    PubMed indexes 3 papers on this condition that name this hospital.

    Also ranked: Respiratory Medicine #2, Thoracic Surgery nominated in the Fudan list.

  4. Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院

    Wuhan 武汉市

    National key clinical specialty

    Also ranked: General Surgery #6, Urology #5, Gynecology #2 in the Fudan list.

  5. Shaanxi Provincial People's Hospital陕西省人民医院

    Xi'an 西安市

    National key clinical specialty

    Published research

    PubMed indexes 2 papers on this condition that name this hospital.

Clinical trials (investigational treatments)

In addition to standard care, clinical research studies for Stomach cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.

  1. Study Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Adenocarcinoma of the Gastric and Oesophagogastric Junction: an Open-label, Prospective, Multicenter, Randomised, Phase 2 Trial.

    Hospital
    The Sixth Affiliated Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06510010

  2. Study Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer

    Status
    Recruiting
    Registry
    NCT06979895

  3. Study The Application and Effect of Goal-oriented Albumin Infusion in the Control of Postoperative Complications in Patients With Gastric Cancer - a Single-center Prospective Non- Randomized Controlled Study

    Lead investigator
    Yuchen Guo, Ph.D. · Prof.
    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT07119463

  4. Study Establishing an Innovative Cohort for Chinese Early Gastric Cancer Patients Based on the National Clinical Research Center for Digestive Diseases Prospective Database: A Retrospective Study

    Lead investigator
    JunZhang · Chief Surgeon
    Hospital
    Beijing Friendship Hospital, Capital Medical University
    Status
    Recruiting
    Registry
    NCT07747688

  5. Study A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer with SOX Plus Tislelizumab Combined with HIPEC

    Lead investigator
    Yan Shi
    Status
    Recruiting
    Registry
    NCT06760858
46 more registered studies

  1. Study A Multicenter, Prospective, Randomized Controlled Clinical Study of Robotic Versus Laparoscopic Radical Surgery for Locally Advanced Gastric Cancer

    Lead investigator
    Yan Shi
    Status
    Recruiting
    Registry
    NCT06791538

  2. Study Comparison of Gastroesophageal Reflux and Quality of Life Between Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer Patients

    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT07635836

  3. Study A Study on the Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer Patients Treated With Chemotherapy and Immunotherapy

    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT07537348

  4. Study A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer

    Hospital
    Jiangsu Province Hospital
    Status
    Recruiting
    Registry
    NCT06555471

  5. Study The Clinical Significance of Examining Metastatic Lymph Nodes in Respective Gastric Mesenteries in the Gastric Cancer Patients Who Received D2 Lymphadenectomy Plus Complete Mesogastric Excision

    Lead investigator
    Jichao Qin · professor
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT07139418

  6. Study A Prospective Cohort Study on Serum Immune Protein Signature for Predicting Neoadjuvant Therapy Efficacy in Advanced Gastric Cancer

    Hospital
    Zhongshan Hospital
    Status
    Recruiting
    Registry
    NCT06662110

  7. Study A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy

    Hospital
    Peking University Cancer Hospital
    Status
    Recruiting
    Registry
    NCT06221748

  8. Study Single Center, Phase II Clinical Study of PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

    Hospital
    Peking University Third Hospital
    Status
    Recruiting
    Registry
    NCT06792162

  9. Study A Prospective, Single-Arm, Phase Ⅱ Clinical Trial Evaluating Fruquintinib in Combination With Paclitaxel for Injection (Albumin-bound) and Iparomlimab and Tuvonralimab Injection as Second-Line Therapy in Advanced Gastric Cancer Patients Previously Received Immunotherapy

    Lead investigator
    Dai, Guanghai · Professor,Chief Physician
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07392346

  10. Study Fecal Microbiota Transplantation Combined with SOX and Sintilimab As First-line Treatment for Advanced Gastric Cancer:A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study (FMT-JSNO-01)

    Lead investigator
    Hua Jiang · MD
    Hospital
    Changzhou No.2 People's Hospital
    Status
    Recruiting
    Registry
    NCT06405113

  11. Study Perioperative S-1 Plus Oxaliplatin Combined With Serplulimab or Placebo for Locally Advanced Gastric Adenocarcinoma With Proficient Mismatch Repair: a Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study

    Lead investigator
    Yu jiren · Professor
    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT05872685

  12. Study A Prospective, Multicentre, Double-blind Randomized Controlled Clinical Study of the Efficacy and Safety of Taurine Combined With Serplulimab and Chemotherapy Versus Serplulimab Combined With Chemotherapy for Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Hospital
    Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
    Status
    Recruiting
    Registry
    NCT06128252

  13. Study A Radio-Pathomic Multimodal Machine Learning Model for Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer: A Retrospective Observational Study

    Hospital
    The Sixth Affiliated Hospital, Sun Yat-sen University
    Status
    Recruiting
    Registry
    NCT06451393

  14. Study A Single-arm, Open-label, Multicenter Phase 2 Study to Evaluate XELOX + Tislelizumab in Combination With Doxorubicin Hydrochloride Liposome Injection （XELOX+PD-1+PLD）as Neoadjuvant Therapy for Resectable Gastric Cancer

    Lead investigator
    Qi Li · Chief Physician
    Hospital
    Shanghai General Hospital
    Status
    Recruiting
    Registry
    NCT05536102

  15. Study A Multicenter, Prospective, Observational Cohort Study to Assess the Safety and Efficacy of Robotic Assisted Surgery Using Vessel Sealer Extend in Locally Advanced Gastric Cancer (STARS-GC09)

    Lead investigator
    Quan Wang · Director, Clinical Professor
    Hospital
    The First Hospital of Jilin University
    Status
    Recruiting
    Registry
    NCT06881043

  16. Study Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

    Hospital
    Tianjin Medical University Cancer Institute & Hospital
    Status
    Recruiting
    Registry
    NCT06560528

  17. Study Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery

    Lead investigator
    Tao Fu · Director of Department of GI Surgery II
    Hospital
    Renmin Hospital of Wuhan University
    Status
    Recruiting
    Registry
    NCT03972956

  18. Study A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Gastrectomy in Neoadjuvant Gastric Cancer Patients

    Hospital
    The Affiliated Hospital of Qingdao University
    Status
    Recruiting
    Registry
    NCT06042998

  19. Study Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer: a Single-arm, Open Clinical Study

    Hospital
    The First Affiliated Hospital of Fujian Medical University
    Status
    Recruiting
    Registry
    NCT06791083

  20. Study Development and Validation of an Explainable Artificial Intelligence Model for Early Gastric Cancer Diagnosis Using Multimodal Endoscopic Imaging

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07551466

  21. Study A Phase II, Open-Label, Multicenter Trial Comparing Disitamab Vedotin Plus Sintilimab and S-1 With Trastuzumab Plus Chemotherapy ± Sintilimab for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RCTS2)

    Lead investigator
    Lian Liu, MD, PHD · Director
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT06730373

  22. Study Efficacy and Safety of Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids in Gastric Cancer Malignant Ascites: a Phase I/II Clinical Study (IPIZA)

    Lead investigator
    Lian Liu, MD, PHD · Professor
    Hospital
    Qilu Hospital of Shandong University
    Status
    Recruiting
    Registry
    NCT06759064

  23. Study A Prospective, Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Patients With Advanced Gastric Cancer

    Lead investigator
    Xiangyu Kong
    Status
    Recruiting
    Registry
    NCT06346093

  24. Study A Randomized, Controlled, Open-Label, Multicenter Clinical Trial Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression

    Hospital
    First Affiliated Hospital of Guangzhou Medical University
    Status
    Recruiting
    Registry
    NCT07788196

  25. Study Prospective, Phase II Clinical Study of Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer

    Hospital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Status
    Recruiting
    Registry
    NCT06487429

  26. Study Clinical Study of SHR1701 in Combination With CAPOX and SHR2554 or Apatinib for First-line Treatment of Advanced Gastric Cancer

    Lead investigator
    Yongxu Jia · Chief Investigator
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Recruiting
    Registry
    NCT07294664

  27. Study Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study

    Lead investigator
    Jichao Qin · Professor
    Hospital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Status
    Recruiting
    Registry
    NCT06728878

  28. Study Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer : a Phase Il Study

    Lead investigator
    Zhongguang Luo, MD · Chief Physician
    Hospital
    Huashan Hospital
    Status
    Recruiting
    Registry
    NCT06054906

  29. Study A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer

    Lead investigator
    YiHui Guan · Professor
    Hospital
    Huashan Hospital
    Status
    Recruiting
    Registry
    NCT07707531

  30. Study Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study

    Hospital
    Zhongshan Hospital
    Status
    Recruiting
    Registry
    NCT05347524

  31. Study Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric：MetBio-GC

    Hospital
    Ruijin Hospital
    Status
    Recruiting
    Registry
    NCT07076979

  32. Study A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

    Hospital
    Sun Yat-sen University Cancer Center
    Status
    Recruiting
    Registry
    NCT05365581

  33. Study The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

    Lead investigator
    Lin Chen · Prof.
    Hospital
    Chinese PLA General Hospital
    Status
    Recruiting
    Registry
    NCT07212933

  34. Study A Prospective Exploratory Study of a HIPEC Priming Strategy Followed by Serplulimab Combined With SOX/XELOX as Neoadjuvant Therapy for Locally Advanced Gastric Cancer

    Lead investigator
    weijun wang
    Status
    Not yet recruiting
    Registry
    NCT07621484

  35. Study Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Open-Label, Randomized, Multi-Centered Phase III Trial

    Lead investigator
    Yihong Sun · Chief of Gastrointestinal Surgery Department
    Hospital
    Zhongshan Hospital
    Status
    Not yet recruiting
    Registry
    NCT07508956

  36. Study A Single-arm, Open-label Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Hypoxia-Inducible CD73/AXL-Targeting CAR-T Cells (XW-LTH-03) in Patients With Advanced Gastric Cancer

    Hospital
    Zhongshan Hospital
    Status
    Not yet recruiting
    Registry
    NCT07333573

  37. Study A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

    Lead investigator
    Zheng Zhichao · Offices Director
    Hospital
    Liaoning Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07132528

  38. Study A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical Surgery

    Lead investigator
    Zheng Guoliang · Vice Offices Director
    Hospital
    Liaoning Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07149181

  39. Study A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

    Lead investigator
    Zheng Zhichao · Offices Director
    Hospital
    Liaoning Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT06764251

  40. Study A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer

    Lead investigator
    Chang-Ming Huang, Prof. · Professor
    Hospital
    Fujian Medical University Union Hospital
    Status
    Not yet recruiting
    Registry
    NCT05235932

  41. Study A Prospective, Multicenter, Phase III Randomized Controlled Trial Evaluating the Impact of Radical Surgery Versus Non-Surgery on Prognosis and Quality of Life in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy (ALANO Study, CGCA2603 Study)

    Lead investigator
    Hua Huang, MD, PhD · Professor, Department of Gastric Surgery, Fudan University Shanghai Cancer Center
    Hospital
    Peking University Cancer Hospital
    Status
    Not yet recruiting
    Registry
    NCT07789184

  42. Study Effect of Prophylactic Hyperthermic Intraperitonal Chemotherapy（HIPEC）After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer（cT3N+M0 and cT4aN+/-M0）: A Randomized-controlled Study

    Hospital
    The First Hospital of Jilin University
    Status
    Not yet recruiting
    Registry
    NCT06525714

  43. Study TACE Combined With Thermal Ablation and Antibody-drug Conjugates, Immune Checkpoint Inhibitors, and Chemotherapy as First-line Treatment for HER2-highly-expressing Gastric Cancer With Liver Metastases: a Multicenter, Single-arm Prospective Clinical Study.

    Hospital
    Shandong Provincial Hospital
    Status
    Not yet recruiting
    Registry
    NCT07602140

  44. Study Clinical Efficacy and Safety Evaluation of Submucosal Injection of Indocyanine Green Tracer in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer: a Prospective, a Multicenter, Randomized, Controlled Study Clinical Trial

    Lead investigator
    Wenbin Yu · Professor， and Chief of Gastrointestinal Surgery Department
    Hospital
    Qilu Hospital of Shandong University
    Status
    Not yet recruiting
    Registry
    NCT06421220

  45. Study A Prospective, Single-center, Phase II Clinical Study of First-line Treatment for HER2 (Human Epidermal Growth Factor Receptor 2) Overexpressing Advanced Gastric Cancer With Disitamab Vedotin in Combination With Cadonilimab

    Lead investigator
    Yongxu Jia · Chief Physician
    Hospital
    First Affiliated Hospital of Zhengzhou University
    Status
    Not yet recruiting
    Registry
    NCT06492317

  46. Study Liposomal Irinotecan in Combination with Sintilimab in Second-Line Treatment of Progressive Gastric Cancer, a Single-Arm, Single-Center, Open-Label, Phase II Clinical Study

    Lead investigator
    Hao Li · Principal Investigator
    Hospital
    Ruijin Hospital
    Status
    Not yet recruiting
    Registry
    NCT06697366

This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.

Hospitals with a national key specialty record

Show the hospital records 5 hospitals with a key-specialty record

Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.

Hospital City Specialty (as published) Evidence Source
Cancer Hospital of Chinese Academy of Medical Sciences中国医学科学院肿瘤医院 Beijing 北京市 Gastrointestinal Surgery 结直肠外科 Level B https://www.cicams.ac.cn/news/401.html
China-Japan Friendship Hospital中日友好医院 Beijing 北京市 Gastrointestinal Surgery 肛肠科 Level B https://www.zryhyy.com.cn/zryh/c100020/202309/47e8245aa93343baac89762d4e80580f.shtml
West China Hospital, Sichuan University四川大学华西医院 Chengdu 成都市 Gastrointestinal Surgery 结直肠肿瘤中心 Level A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院 Wuhan 武汉市 Gastrointestinal Surgery 普通外科：胃肠外科 Level B https://www.tjh.com.cn/contents/934/27291.html
Shaanxi Provincial People's Hospital陕西省人民医院 Xi'an 西安市 Gastrointestinal Surgery 胃肠外科 Level B https://www.spph-sx.com/zlfw1/zdzk.htm

5 hospitals with a matching national key specialty record.

Values written in Chinese are quoted as published by the source.

Questions about this condition

We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.

Ask us about this condition

ICD codes

Show the code table 10 ICD codes
Version Code Name in that version
ICD-10-WHO C16 Malignant neoplasm of stomach
ICD-10-WHO C16.0 Cardia
ICD-10-WHO C16.1 Fundus of stomach
ICD-10-WHO C16.2 Body of stomach
ICD-10-WHO C16.3 Pyloric antrum
ICD-10-WHO C16.4 Pylorus
ICD-10-WHO C16.5 Lesser curvature of stomach, unspecified
ICD-10-WHO C16.6 Greater curvature of stomach, unspecified
ICD-10-WHO C16.8 Overlapping lesion of stomach
ICD-10-WHO C16.9 Stomach, unspecified

Rows are the WHO ICD-10 entries for this condition, quoted as published.

Source & evidence

Source URL
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Source scheme
https
Source type
Provincial health commission
Evidence level
A - said by a provincial health commission or university
Retrieved on
2026-09-24